Fig. 6

IL-1 blockade suppresses cetuximab-induced NK cell activity. Normal human peripheral blood mononuclear cells (PBMCs) were cultured at 10:1 and 1:1 effector/target ratio for 6 h at 37 °C with SQ20B cells that were treated with cetuximab with or without anakinra. Culture media containing PBMCs were then stained with anti-CD3, anti-CD16, anti-CD54 and anti-CD107a antibodies conjugated to different fluorochromes. NK cells, gated on CD3− cells in the lymphocyte FSC/SSC subset were analyzed for the expression of CD16 (a) and CD54 (b) and CD107a (c). Error bars = SD, *:p < 0.05 vs cetuximab+anakinra